Skip to main content

Deadline Approaching: Inspire Medical Systems, Inc. (INSP) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Law Offices of Howard G. Smith reminds investors of the upcoming January 5, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, inclusive (the “Class Period”).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INSPIRE MEDICAL SYSTEMS, INC. (INSP), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On August 4, 2025, Inspire disclosed that the launch of its new sleep apnea device, the Inspire V, was facing an “elongated timeframe” due to several issues, including “many centers [not completing] the training, contracting and onboarding criteria required prior to the purchase and implant of Inspire V,” “software updates for claims submissions and processing” not taking effect until early July, and excess inventory causing poor demand. Further, the Company reduced its 2025 earnings guidance by more than 80%, from $2.20 to $2.30 per share to $0.40 to $0.50 per share.

On this news, Inspire’s stock price fell $42.04, or 32.4%, to close at $87.91 per share on August 5, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) demand for Inspire V was poor, as providers had significant amounts of surplus inventory and were reluctant to transition to a new treatment; (2) Inspire failed to complete training and onboarding for “many” of its treatment center customers; failed to set up basic IT systems, including a customer approval process; failed to ensure that critical insurer claims software was properly updated to facilitate claims processing and payment; and failed to ensure that Medicare reimbursement was in place at the time of the launch; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Inspire common stock during the Class Period, you may move the Court no later than January 5, 2026 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements.

Contact Us To Participate or Learn More:

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,

3070 Bristol Pike, Suite 112,

Bensalem, Pennsylvania 19020,

Telephone: (215) 638-4847

Email: howardsmith@howardsmithlaw.com,

Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  231.63
-3.06 (-1.30%)
AAPL  266.37
-6.04 (-2.22%)
AMD  238.75
-8.06 (-3.26%)
BAC  51.55
-1.06 (-2.01%)
GOOG  285.20
+8.22 (2.97%)
META  597.34
-12.12 (-1.99%)
MSFT  506.30
-3.88 (-0.76%)
NVDA  184.91
-5.26 (-2.77%)
ORCL  217.58
-5.27 (-2.36%)
TSLA  406.94
+2.59 (0.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.